PACS — PACS Group, Inc.

PACS Group Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Performance:
  • Revenue: $1.36 billion (up 12% year-over-year)
  • Net Income: $59.8 million
  • Adjusted EBITDAR: $237.7 million
  • Adjusted EBITDA: $142.1 million
• Full Year 2025 Performance:
  • Total Revenue: $5.29 billion (up 29% from 2024)
  • Net Income: $191.5 million (EPS: $1.22)
  • Adjusted EBITDAR: $883.9 million
  • Adjusted EBITDA: $505 million
  • Average Occupancy: 89.1% (Mature facilities: 94.9%)
  • Net Leverage: Approximately 0.3x

2. Strategic Updates and Business Highlights

• PACS executed 8 strategic acquisitions in 2025, focusing on enhancing local scale and density within existing markets.
• Continued integration of facilities acquired in 2024, with a strong emphasis on operational excellence and clinical outcomes.
• Notable improvements in quality metrics: 73.4% of skilled nursing facilities rated 4 or 5 stars by CMS, with an average star rating increase from 4.3 to 4.4.
• Successful completion of 7 zero-deficiency surveys, reflecting strong regulatory compliance and operational execution.
• Investment in leadership development through the Administrator in Training program, with 38 trainees currently in the program.

3. Forward Guidance and Outlook

• 2026 Guidance:
  • Expected Revenue: $5.65 billion to $5.75 billion (approx. 8% growth)
  • Expected Adjusted EBITDA: $555 million to $575 million (approx. 12% growth)
• Focus on integrating and optimizing the expanded portfolio, investing in clinical capabilities, and maintaining disciplined capital allocation for acquisitions.

4. Bad News, Challenges, or Points of Concern

• Ramping facilities reported a decline in occupancy to 86.3% from over 93% the previous year, attributed to the transition of facilities into ramping status.
• New facilities averaged 81.1% occupancy, down from 82.8% in 2024, indicating challenges in stabilization post-acquisition.
• The competitive landscape remains challenging, with rising costs in real estate and operational expenses due to inflation impacting acquisition pricing.

5. Notable Q&A Insights

• Payer Conversations: The company is seeing increased interest from insurers as quality metrics improve, positioning PACS as an attractive partner for managed care contracts.
• M&A Pipeline: PACS anticipates acquiring about 20 facilities annually, with a focus on distressed assets that can benefit from their operational model. The company is also looking to acquire real estate alongside operational transactions.
• De Novo Activity: While not a primary growth strategy, PACS is open to de novo projects in favorable markets, although acquisitions remain the focus.
• Value-Based Purchasing: Management expressed confidence in adapting to new reimbursement models tied to quality metrics, suggesting that PACS is well-positioned to benefit from these changes.

Overall, PACS Group demonstrated strong financial performance and operational execution in 2025, with a positive outlook for 2026 despite some challenges in occupancy rates for newly acquired facilities.